Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance-Reference-Cited by-同舟云学术

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance

Published:2018-08 Issue:2 Volume:150 Page:239-246
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Lindemann Kristina,Gao Bo,Mapagu Cristina,Fereday Sian,Emmanuel Catherine,Alsop Kathryn,Traficante Nadia,Harnett Paul R.,Bowtell David D.L.,deFazio Anna^ORCID

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference25 articles.

1. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann. Oncol./ESMO,2013

2. Clinical trials in recurrent ovarian cancer;Friedlander;Int. J. Gynecol. Cancer,2011

3. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer;Vergote;Int. J. Gynecol. Cancer,2010

4. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial;Pujade-Lauraine;J. Clin. Oncol.,2014

5. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist);Lindemann;Br. J. Cancer,2017

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models;Heliyon;2024-08

2. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

3. Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer;2024-07-18

4. A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia;Current Oncology;2024-03-04

5. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target;BMC Genomics;2024-02-16